RxDoctor Payments Data

Daniel Seeser, MD

Family Medicine · Lake Charles, LANPI 1376162990

Payments from drug & device makers

$3,062in general payments, 2019–2025

Across 163 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$627
  • AstraZeneca$460
  • Novo Nordisk$279
  • Abbott$185
  • Astellas Pharma US Inc$176
  • Lilly USA, LLC$170
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,04699%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,062 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$115,388
Medicare patients
226
Services billed
2,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide122$148,630
OzempicSemaglutide125$129,710
JardianceEmpagliflozin86$78,000
FarxigaDapagliflozin Propanediol81$67,948
TrulicityDulaglutide45$54,310
EliquisApixaban62$50,327
JanuviaSitagliptin Phosphate18$21,816
MyrbetriqMirabegron37$20,316
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog37$19,699
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,815
Repatha SureclickEvolocumab21$11,656
TradjentaLinagliptin20$9,962
JanumetSitagliptin Phos/Metformin Hcl13$9,431
Spiriva RespimatTiotropium Bromide13$6,449
JentaduetoLinagliptin/Metformin Hcl12$6,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$170$202,941167 claims
Novo NordiskOzempic$279$129,710125 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Jentadueto$23$100,677131 claims
AstraZenecaFarxiga$460$67,94881 claims
PfizerEliquis$92$50,32762 claims
MerckJanuvia, Janumet$48$31,24731 claims
Astellas Pharma US IncMyrbetriq$176$20,31637 claims
GSKTrelegy Ellipta$31$13,81517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →